Unnatural Products, Inc.

Unnatural Products has developed an AI-driven platform that engineers synthetic macrocycles—molecules inspired by nature’s own solutions—to target previously undruggable intracellular proteins. Their technology enables the creation of orally bioavailable peptide therapeutics with high specificity and stability. The company has secured major partnerships with Merck & Co. ($220M+ collaboration) and BridgeBio Pharma (option exercised for rare disease/oncology candidates), validating their approach as a next-generation modality for high-unmet need indications such as cancer and rare genetic disorders[2][5][8]. Clinical results have not yet been published; programs are advancing through preclinical development in partnership pipelines.